Introduction
============

Chronic obstructive pulmonary disease (COPD) of the lungs involves irreversible airway obstruction and abnormal, chronic inflammation of the airway.[@b1-copd-10-715] Smoking is a key risk factor of COPD: it strongly induces the release of inflammatory mediators, including oxidants and proteases, which ultimately trigger chronic airway inflammation and emphysema.[@b2-copd-10-715] Emphysema is a complication of COPD that arises when chronic inflammation in the lung destroys the normal balance between the activity of metalloproteases like matrix metalloproteinases (MMPs) and the activity of anti-metalloproteases like tissue inhibitor of metalloproteinase (TIMPs), resulting in abnormally enhanced MMP activity.[@b3-copd-10-715],[@b4-copd-10-715]

Smoking cessation may partially restore pulmonary function and lung density in patients with stable COPD,[@b5-copd-10-715],[@b6-copd-10-715] whereas co-administration of anti-inflammatory drugs is a must in order to control chronic airway inflammation and progression of emphysema. Not all patients with COPD respond equally well to the medical treatment; for example, patients without emphysema respond much better than those with severe emphysema do.[@b7-copd-10-715]

Efforts have been made to identify more universally effective anti-inflammatory drugs to treat COPD, and researchers' interest has been gradually focused on peroxisome proliferator-activated receptors (PPARs). These ligand-activated transcription factors belong to a nuclear hormone receptor family[@b8-copd-10-715] and appear to regulate immune and inflammatory responses by inhibiting the expression of proinflammatory genes.[@b9-copd-10-715],[@b10-copd-10-715] The most extensively studied PPAR subtype is PPARγ, which is involved in a wide spectrum of lung diseases, including pulmonary vascular disease, acute lung injury, asthma, and lung cancer.[@b11-copd-10-715]--[@b14-copd-10-715] PPARγ agonists have immunomodulating effects that lead to reduced secretion of inflammatory cytokines in articular cell culture or experimental models of arthropathy.[@b15-copd-10-715],[@b16-copd-10-715] They also repress the synthesis of extracellular matrix components in various cell types, such as collagen synthesis by thiazolidinediones in mesangial cells from diabetic rats[@b17-copd-10-715] and Wy14643 synthesis in hepatic stellate cells from rats with cholestatic liver fibrosis.[@b18-copd-10-715] Recently, PPARγ agonists have begun to be used as an anti-inflammatory therapy for COPD.[@b10-copd-10-715],[@b15-copd-10-715]

One unresolved question is whether PPARγ agonists help reverse the metalloprotease/anti-metalloprotease imbalance associated with emphysema. In this study, we used a rat model of smoking-induced emphysema to examine how rosiglitazone (Sigma-Aldrich Co., St Louis, MO, USA), one of the PPARγ agonists, affected COPD pathology. We examined whether rosiglitazone altered the metalloprotease/anti-metalloprotease imbalance, and explored the molecular mechanism underlying the imbalance.

Materials and methods
=====================

Animal model
------------

All experiments were conducted in accordance with the guidelines of the Research Ethics Committee of China Medical University. Male Wistar rat weanlings (weighing 170--210 g) were obtained from the Laboratory Animal Center of China Medical University and randomly assigned into three groups with 12 animals in each group. The cigarette smoke (CS) group was exposed to smoke from 16 commercial cigarettes (Altria Group Inc, Richmond, VA, USA); each of these cigarettes contained 0.9 mg nicotine, 14 mg CO, and 12 mg tar oil, according to the manufacturer's specifications. Animals were exposed to smoke (scope, 8% v/v) with the cigarette filters removed for 30 minutes, twice a day, 6 days per week for 12 weeks. The rosiglitazone-CS (RCS) group was exposed to CS in the same way as the CS group but in the presence of rosiglitazone, intragastrically administered once daily (30 mg/kg, dissolved in normal saline). The control group and CS group received a daily orally administered injection of saline vehicle without any smoke.

At the end of the 12th week, rats were sacrificed by exsanguination and lungs were excised. The right upper lobes were removed and stored at -80°C, and the right median lobes were embedded in paraffin.

Lung tissue histology and morphometric analysis
-----------------------------------------------

Paraffin-embedded sections of tissues were stained with hematoxylin-eosin and examined by light microscopy at a total magnification of 100×. Interalveolar wall distance was measured as mean linear intercept (MLI), defined as the total length of the test line divided by the number of alveolar walls intersecting it.[@b19-copd-10-715] Alveolar density was measured as mean alveolar number (MAN), defined as the number of alveoli in each field.[@b19-copd-10-715] MLI and MAN were calculated for each sample based on ten random fields.

Levels of MMP2 and MMP9 proteins in lung tissue
-----------------------------------------------

Lung tissues were homogenized and lysed. Nuclear and cytoplasmic fractions were prepared as previously described.[@b20-copd-10-715] The cell lysates (20 μg for each lane) were subjected to 10% polyacrylamide gel electrophoresis (PAGE), and the separated protein was subsequently transferred onto a nitrocellulose membrane by electroblotting. The membrane was blocked for 1 hour at room temperature with blocking solution. The blot was then incubated overnight at 4°C with mouse anti-MMP2 antibody (1:500; Abcam PLC, Cambridge, UK) or anti-MMP9 antibody (1:500; Abcam PLC). The primary antibody was removed by washing the blot three times, and the membrane was next incubated with secondary antibody (1:2,000 dilution) for 2 hours at room temperature. The signals were detected using enhanced chemiluminescence (GE Healthcare UK Ltd, Little Chalfont, UK), and the protein bands were desitometrically analyzed with β-actin as a loading control (Metamorph/Evolution MP 5.0/B X51, Olympus, US).

To complement these Western blotting studies, we also examined protein signal intensity in situ using immunohistochemistry of lung tissue sections. Sections were cleared of paraffin, endogenous peroxidases were blocked using 3% H~2~O~2~, and sections were washed and incubated with rabbit serum for 10 minutes at room temperature. Sections were then incubated overnight at 4°C with mouse antibody against MMP2 (1:50; Abcam) or MMP9 (1:50; Abcam). Finally, sections were incubated with biotinylated rabbit anti-mouse or goat anti-rabbit immunoglobulin G (IgG) (1:2,000; Santa Cruz Biotechnology Inc, Dallas, TX, USA). Sections were stained with diaminobenzidine (Sinopharm, Shanghai, People's Republic of China) according to the manufacturer's instructions. Five sections from each animal were analyzed, and four images were acquired from one randomly selected location per section. Digital photos were analyzed using Image-Pro Plus 6.0; the analyst was blind to group allocation of the tissue sections.

To verify signal specificity for MMP2 and MMP9, sections were incubated with only primary or secondary antibody in parallel with the experimental samples. Positive staining was not observed in any case.

Determination of MMP2 and MMP9 activity in lung tissues
-------------------------------------------------------

The resected lung tissues of each group were homogenized and the activity of MMP2 and MMP9 was quantitatively determined using MMP2 and MMP9 Biotrak™ activity assay kit (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA).

Apoptosis analysis
------------------

The alveolar cell type I was isolated as previously described,[@b21-copd-10-715] the isolated cells were resuspended in phosphate-buffered saline (PBS), and then fixed in ethanol under room temperature overnight. The cells were washed with PBS and resuspended in staining solution (50 mg/mL propidium iodide, 1 mg/mL RNase A, and 0.1% Triton X-100 in PBS, all purchased from Thermo Fisher Scientific, Waltham, MA, USA). The stained cells were then analyzed for apoptosis with a BD flow cytometer (BD Biosciences, San Jose, CA, USA).

Levels of PPARγ, phospho-MAPK and activated NFκB proteins in lung tissue
------------------------------------------------------------------------

Cytoplasmic fractions containing 50 μg of total protein were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes. The membrane was blocked for 1 hour at room temperature with a blocking solution. The blot was then incubated overnight at 4°C with mouse anti-di-phosphorylated extracellular-signal-regulated kinases1 and 2 (ERK1/2) (1:500; Abcam), anti-phospho-JNK (c-Jun N-terminal kinase) (1:500; Abcam), or anti-phospho-p38 (1:500; Abcam). After three washing steps, the membrane was incubated with secondary antibody (1:2,000 dilution) for 2 hours at room temperature. The signals were detected using enhanced chemiluminescence (GE Healthcare UK Ltd), and the protein bands were densitometrically analyzed with β-actin as a loading control (Metamorph/Evolution MP 5.0/B X51).

To determine the level of NFκB activation in lung tissue, the p65 fraction of NFκB and IκBα (1:500; Abcam) in nuclear extracts was analyzed by Western blotting. Nuclear extracts containing 50 μg of total protein were resolved by 10% SDS-PAGE, and NFκB was detected using rabbit polyclonal antibody against NFκB p65 (1:500; Abcam) or anti-IκBα (1:500, Abcam). As a loading control, actin levels were determined using a mouse antibody against actin (1:1,000; Abcam). Blots were incubated with secondary antibody, processed for chemiluminescence, and analyzed as described in this section. Band intensities were quantified using ImageJ software 1.42q and normalized to levels in the control group, as described in this section. Experiments were performed three times for each experimental condition.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS version 11.5 (SPSS Inc, Chicago, IL, USA). All data were expressed as means ± standard deviation (SD). Differences among more than two groups were compared using one-way analysis of variance (ANOVA); differences between two groups were compared using Fisher's least significant difference test. Significance of correlation between two variables was assessed using the Pearson correlation coefficient. The threshold for significance was set at *P*\<0.05.

Results
=======

PPARγ upregulation by rosiglitazone partially protects against emphysema induced by CS
--------------------------------------------------------------------------------------

In this study, we analyzed the possible effect of PPARγ activation by administration of rosiglitazone on lung morphology when exposed to cigarette smoking. MLI and MAN were measured to compare CS-induced lung emphysema and rosiglitazone-treated emphysema to evaluate the protective effect of PPARγ. Cigarette smoke exposure caused significantly decreased expression of PPARγ ([Figure 1](#f1-copd-10-715){ref-type="fig"}) and increases in MLI and MAN in the CS group when compared to the control group ([Figure 2](#f2-copd-10-715){ref-type="fig"}). When simultaneously treated with rosiglitazone and CS exposure, the changes of emphysema were partially prevented with increased MLI and MAN and the increased expression of PPARγ compared with the CS group ([Figures 1](#f1-copd-10-715){ref-type="fig"} and [2](#f2-copd-10-715){ref-type="fig"}; [Table 1](#t1-copd-10-715){ref-type="table"}).

We compared the lung tissue damage caused by CS in the presence or absence of the PPARγ agonist rosiglitazone. The CS group showed significantly downregulated expression of PPARγ protein ([Figure 1](#f1-copd-10-715){ref-type="fig"}) as well as decreases in MLI and MAN ([Figure 2](#f2-copd-10-715){ref-type="fig"}), as compared with the control group. The RCS group showed higher levels of PPARγ protein than that of the CS group and lower than that of the control group; both the Western blotting and immunochemistry revealed similar results ([Figure 1](#f1-copd-10-715){ref-type="fig"}). Meanwhile, the values of MLI and MAN were higher than those of the CS group and lower than those of the control group ([Figure 2](#f2-copd-10-715){ref-type="fig"}).

Rosiglitazone suppressed CS-induced increases in MMP2 and MMP9 protein levels
-----------------------------------------------------------------------------

In order to assess the inhibitory effect of rosiglitazone on the abnormally enhanced MMP activity associated with emphysema, which thereby helps to restore the metalloprotease/anti-metalloprotease balance, we measured protein levels and activities of MMP2 and MMP9 in rats exposed to CS with or without treatment of rosiglitazone. The CS group showed significantly higher levels of both protein expression levels (Western blot, [Figure 3A, B](#f3-copd-10-715){ref-type="fig"}; immunohistochemistry, [Figure 3E](#f3-copd-10-715){ref-type="fig"}), and MMP2 and MMP9 activities ([Figure 3C, D](#f3-copd-10-715){ref-type="fig"}), than the other two groups. The protein expression levels and activities of MMP2 and MMP9 in the RCS group were all higher than in the control group ([Figure 3](#f3-copd-10-715){ref-type="fig"}).

Rosiglitazone inhibits CS-induced activation of NFκB
----------------------------------------------------

The CS group showed higher levels of NFκB p65 protein than the other two groups; levels in the RCS group were higher than the control group, as determined by Western blot ([Figure 4](#f4-copd-10-715){ref-type="fig"}) and immunohistochemistry ([Figure 5](#f5-copd-10-715){ref-type="fig"}). In addition to examining levels of NFκB p65, we measured phosphorylation levels of IκBα, which inhibited nuclear NFκB. Levels of IκBα phosphorylation were lower in the CS group than in either of the other two groups; the level in the RCS group was lower than levels in the control group ([Figure 4](#f4-copd-10-715){ref-type="fig"}).

Inhibition of NFκB activation by rosiglitazone involves MAPK signaling
----------------------------------------------------------------------

We wanted to identify which one of several pathways known to regulate NFκB expression also functions as a mediator for the CS-induced activation of transcription factors, as well as for the rosiglitazone-mediated inhibition of this activation. Western blotting showed that levels of phosphorylated p38 and ERK1/2 were higher in the CS group than in the other two groups; these levels in the RCS group were higher than those in the control group ([Figure 6](#f6-copd-10-715){ref-type="fig"}). In contract, the levels of phosphorylated JNK in the three groups presented no significant differences between groups.

Effect of rosiglitazone on the apoptosis status of alveolar cells harvested from rats treated with CS
-----------------------------------------------------------------------------------------------------

To quantitatively determine the number of apoptotic cells, we isolated alveolar cells (type I) following the protocol as described previously,[@b21-copd-10-715] and carried out flow cytometry analysis to determine the ratio of apoptotic cells. As shown in [Figure 7](#f7-copd-10-715){ref-type="fig"}, apoptosis indexes in control, CS, and RCS groups were 5.1%, 28.8%, and 14.4%, respectively.

Discussion
==========

In this rat emphysema model, CS exposure upregulated expression of MMP2 and MMP9, creating an imbalance in the metalloprotease/anti-metalloprotease equilibrium, which is associated with histopathological changes in alveoli. These effects were partially but significantly reversed by administering the PPARγ agonist rosiglitazone, together with the CS. Rosiglitazone appears to work by activating NFκB via a MAPK-dependent signaling pathway.

Our observation that exposure to CS induced over-expression of MMP2 and MMP9 is consistent with the widely accepted notions that proteases make a critical contribution to all the pathologic processes detected in the lungs of COPD patients;[@b22-copd-10-715]--[@b24-copd-10-715] with more specific findings that expression of MMPs 1--3 and 7--9 are higher in COPD patients than in healthy people; and that MMP9 levels correlated with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage of pulmonary function test.[@b24-copd-10-715]

Our observation that PPARγ activation reduced the expression of both MMP2 and MMP9, as well as the lung tissue histopathology characteristic of emphysema, is consistent with the idea that PPARγ protects against CS-induced emphysema. Indeed, we have already shown that exposure to CS decreases PPARγ expression and increases inflammatory cytokine expression in bronchial epithelial cells in vivo and in vitro.[@b25-copd-10-715]

Our study adds emphysema to the types of tissue damage and disease against which PPARγ protects by inhibiting production of the extracellular matrix-degrading MMP9. This has already been shown in human bronchial epithelial cells treated with tumor necrosis factor alpha (TNFα) and phorbol myristate acetate (PMA) in a concentration-dependent manner,[@b26-copd-10-715] as well as in type 2 diabetic patients treated with rosiglitazone.[@b27-copd-10-715] Similarly, the PPARγ agonist pioglitazone inhibits the increase in MMP2 and MMP9 expression induced by renal ischemia/reperfusion injury, reducing the severity of renal injury.[@b27-copd-10-715] Atorvastatin inhibits expression of both MMP9 messenger RNA (mRNA) and protein, while upregulating the expression of all PPAR isoforms; pretreatment with PPAR inhibitors attenuates this inhibition of MMP9 expression.[@b28-copd-10-715] Our study is the first to extend the possibility of PPARγ protection to emphysema and the imbalance of MMPs in emphysema.

We found that while CS increased NFκB expression, PPARγ activation by rosiglitazone partially inhibited this NFκB upregulation. We observed the inverse trend with expression of IκBα, a negative regulator of NFκB. These results are consistent with the idea that NFκB is a key promoter of inflammation, whose activation in the lower airways of patients with COPD will lead to pulmonary emphysema,[@b29-copd-10-715],[@b30-copd-10-715] which is negatively regulated by PPARγ. Once activated, NFκB translocates to the nucleus, where it induces the transcription of proinflammatory genes. Based on experiments in adipose tissue, the RelA subunit of NFκB binds to PPARγ and prevents dimers of PPARγ and retinoid X receptor from binding to target genes.[@b31-copd-10-715] This binding event also leads to nuclear export of NFκB, thereby reducing NFκB-mediated inflammatory gene expression.[@b32-copd-10-715] While signal transduction "cross-talk" between PPARγ and NFκB has been documented in several types of tissue damage and disease, this is the first report suggesting that such cross-talk also occurs in CS-induced emphysema.

Evidence of such cross-talk is consistent with previous work from our laboratory in macrophages harvested from rats exposed to CS for 3 months in vivo, which showed that rosiglitazone counteracted CS-induced leukotriene B4 (LTB4) and interleukin 8 (IL8) release and PPARγ down-regulation, markedly lowering the expression of toll-like receptor 4 (TLR4) and TLR2,[@b25-copd-10-715] and consistent with a study in a mouse model of polymicrobial sepsis due to cecal ligation and puncture.[@b33-copd-10-715] In the latter mouse model, sepsis upregulated NFκB expression and downregulated IκBα expression; both changes were partially inhibited by pioglitazone.

In order to assess what signaling pathways lead to NFκB activation in emphysema, we analyzed levels of p38 MAPK, ERK1/2, and JNK after exposure to CS in the presence or absence of rosiglitazone. We found that smoke exposure increased phosphorylation of ERK1/2 and p38 and decreased PPARγ expression, with no obvious effect on JNK phosphorylation. Exposure to smoke in the presence of rosiglitazone led to smaller increases in phosphorylation of ERK1/2 and p38. These results provide the first evidence that CS activates PPARγ by triggering the phosphorylation of ERK1/2 and p38 MAPK. These findings extend the results of a previous study indicating that MAPK kinase signaling mediates some of the effects of CS on cytokine production.[@b34-copd-10-715] How rosiglitazone inhibits the smoke-induced activation of ERK1/2 and p38 requires further study.

The mechanism of PPARγ regulation observed in the current study in CS-induced emphysema appears to be analogous to that described for other disease models.[@b35-copd-10-715],[@b36-copd-10-715] In a study of apoptosis regulation of human neuroblastoma cells, the PPARγ agonist 15-deoxy-delta 12,14-prostaglandin J2 induced PPARγ expression and activated ERK2, while both these changes were partially inhibited by the PPARγ antagonist GW9662.[@b37-copd-10-715] In a study exploring the mechanism of the rosiglitazone inhibition of TNFα and gamma interferon (IFNγ) inflammatory effects in human endothelial cells, rosiglitazone attenuated the inflammatory response by inhibiting ERK1/2 phosphorylation.[@b38-copd-10-715] Rosiglitazone also rapidly inhibited the homocysteine-induced phosphorylation of ERK1/2 and p38 MAPK in endothelial cells and vascular smooth muscle cells.[@b39-copd-10-715]

This mechanism of PPARγ regulation may not be universal. In a mouse model of polymicrobial sepsis, an increase in nuclear levels of phosphorylated ERK1/2 correlated with a decrease in PPARγ phosphorylation in peripheral blood mononuclear cells; in lung tissue, however, the increase in phosphorylated ERK1/2 was associated with an increase in PPARγ phosphorylation.[@b40-copd-10-715] In MCF7 breast cancer cells, α-eleostearic acid simultaneously inhibited phosphorylation of ERK1/2 and PPARγ in a time-dependent manner.[@b41-copd-10-715] The PPARγ agonist troglitazone upregulated PPARγ expression in the human lung cancer cell lines NCI-H23 and CRL-2066, as well as to a lesser extent in the normal human lung cell line CRL-202.[@b42-copd-10-715] However, in contrast to the results observed in the present study, these troglitazone-induced increases in PPARγ expression were associated with increases in the levels of phosphorylated ERK1/2 and p38 and with decreases in stress-activated protein kinase (SAPK)/JNK activity. The difference between these results and those in our study and related work highlights the multiple signaling pathways that regulate PPARγ activity and the likelihood that the precise pathway involved depends on the physiological process (eg, inflammation, aging, proliferation) and the stimulus (eg, cigarette smoking, inflammatory cytokines).

Conclusion
==========

In summary, our animal model suggests that CS works via signaling pathways dependent on MAPK and NFκB pathways to activate PPARγ, leading in turn to excess MMP2 and MMP9 activity. This metalloprotease/anti-metalloprotease imbalance plays a large part in the emphysematous changes induced by CS. These mechanistic insights may help lead to new therapies for COPD and emphysema.
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![Effects of cigarette smoke (CS) with the treatment rosiglitazone on the protein expression of PPARγ.\
**Notes:** CS stimulation caused the decreased expression of PPARγ (CS group) when compared to the control group, while the treatment of rosiglitazone caused the partial recovery of PPARγ (RCS group). (**A**) The protein expression of PPARγ as measured by Western blotting; (**B**) the target protein bands densitometrically analyzed, normalized to β-actin; (**C**) the protein expression of PPARγ measured by immunochemistry staining (×400 magnification) in the control group, CS group, and RCS group. \**P*\<0.05, compared with the control group; ^▲^*P*\<0.05, compared with the CS group.\
**Abbreviations:** PPARγ, peroxisome proliferator-activated receptor γ; RCS, rosiglitazone-cigarette smoke.](copd-10-715Fig1){#f1-copd-10-715}

![Effects of rosiglitazone on the histopathological changes in lung tissues of cigarette smoke (CS)-induced lung emphysema in rats.\
**Notes:** MLI (mean linear intercept) and MAN (mean alveolar number) were measured to compare the protective effect of PPARγ in CS-induced lung emphysema and rosiglitazone-treated emphysema. When compared to the control group (**A**), CS caused increased MLI and MAN in the CS group (**B**). Compared with the CS group (**B**), rosiglitazone treatment caused decreased MLI and MAN changes (**C**). ×200 magnification.\
**Abbreviation:** PPARγ, peroxisome proliferator-activated receptor γ.](copd-10-715Fig2){#f2-copd-10-715}

![Effects of rosiglitazone on the expression of MMP2 and MMP9 in Cs-induced emphysema in rats.\
**Notes:** Effects of rosiglitazone on the expression of MMP2 and MMP9 in CS-induced emphysema in rats as measured by Western blotting (**A**). The target protein bands were desitometrically analyzed normalized to β-actin (**B**). The activities of MMP2 (**C**) and MMP9 (**D**) in each group were determined by using MMP2 and MMP9 Biotrak™ activity assay. The expression of MMP2 and MMP9 was confirmed by using immunohistochemistry for each group (magnification ×400) (**E**). The values presented are the mean ± SD. \**P*\<0.05, compared with the control group; ^▲^*P*\<0.05, compared with the CS group.\
**Abbreviations:** MMP, metalloprotease; CS, cigarette smoke; SD, standard deviation; RCS, rosiglitazone-cigarette smoke.](copd-10-715Fig3){#f3-copd-10-715}

![Effects of rosiglitazone on the expression of the NFκB p65, IκBα, and pIκBα by Western blotting (**A**). The target protein bands were densitometrically analyzed normalized to β-actin (**B**).\
**Notes:** \**P*\<0.05, compared with the control group; ^▲^*P*\<0.05, compared with the CS group.\
**Abbreviations:** p, protein; NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells; IκBα, nuclear factor of kappa light polypeptide gene enhancer in B-cell inhibitor, alpha; CS, cigarette smoke; RCS, rosiglitazone-cigarette smoke.](copd-10-715Fig4){#f4-copd-10-715}

![Effects of rosiglitazone on the expression of the NFκB p65 in alveolar epithelial cells as determined by immunohistochemistry.\
**Abbreviations:** p65, protein 65; NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells; CS, cigarette smoke; RCS, rosiglitazone-cigarette smoke.](copd-10-715Fig5){#f5-copd-10-715}

![Effects of rosiglitazone on the signaling pathway of MAPK.\
**Notes:** The expression of P38, phospho-P38, ERK1/2, phospho-ERK1/2, JNK, and phospho-JNK was measured by Western blotting (**A**), and the target protein bands were densitometrically analyzed normalized to β-actin (**B**). \**P*\<0.05, compared with the control group; ^▲^*P*\<0.05, compared with the CS group.\
**Abbreviations:** MAPK, mitogen-activated protein kinase; ERK1/2, extracellular signal-regulated kinase-1 and -2; JNK, c-Jun N-terminal kinase; CS, cigarette smoke; RCS, rosiglitazone-cigarette smoke.](copd-10-715Fig6){#f6-copd-10-715}

![Effect of rosiglitazone on apoptosis status of alveolar cells (type I) isolated from control group (**A**), CS group (**B**), and RCS group (**C**).\
**Abbreviations:** CS, cigarette smoke; RCS, rosiglitazone-cigarette smoke.](copd-10-715Fig7){#f7-copd-10-715}

###### 

Comparison of emphysematous changes in the emphysema model and the rosiglitazone-treated emphysema model as compared with the control group

  Group           MLI (μm)                                                                                            MAN (n/HP)                                                                                           MAA (μm^2^)
  --------------- --------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Control group   45.25±7.86                                                                                          105.49±13.69                                                                                         6,012.12±890.48
  CS group        73.56±10.28[\*](#tfn1-copd-10-715){ref-type="table-fn"}                                             50.16±9.56[\*](#tfn1-copd-10-715){ref-type="table-fn"}                                               9,618.89±956.14[\*](#tfn1-copd-10-715){ref-type="table-fn"}
  RCS group       55.69±5.35[\*](#tfn1-copd-10-715){ref-type="table-fn"}[▲](#tfn2-copd-10-715){ref-type="table-fn"}   61.17±10.75[\*](#tfn1-copd-10-715){ref-type="table-fn"}[▲](#tfn2-copd-10-715){ref-type="table-fn"}   8,012.15±1,168.56[\*](#tfn1-copd-10-715){ref-type="table-fn"}[▲](#tfn2-copd-10-715){ref-type="table-fn"}
  F value         37.63                                                                                               78.30                                                                                                38.25

**Notes:**

*P*\<0.01, compared with the control group;

*P*\<0.05, as compared with the control group.

**Abbreviations:** CS, cigarette smoke; RCS, rosiglitazone-cigarette smoke; MLI, mean linear intercept; MAA, mean alveolar area; MAN, mean alveolar number.
